252 related articles for article (PubMed ID: 32026050)
21. Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers.
Cassinelli G; Pasquali S; Lanzi C
Front Oncol; 2022; 12():965261. PubMed ID: 36119484
[TBL] [Abstract][Full Text] [Related]
22. Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma.
Jagosky MH; Anderson CJ; Symanowski JT; Steuerwald NM; Farhangfar CJ; Baldrige EA; Benbow JH; Livingston MB; Patt JC; Ahrens WA; Kneisl JS; Kim ES
Cancer Med; 2023 Mar; 12(6):7029-7038. PubMed ID: 36464833
[TBL] [Abstract][Full Text] [Related]
23. Application of MDM2 Fluorescence In Situ Hybridization and Immunohistochemistry in Distinguishing Dedifferentiated Liposarcoma From Other High-grade Sarcomas.
Song MJ; Cho KJ; Lee JS; Song JS
Appl Immunohistochem Mol Morphol; 2017; 25(10):712-719. PubMed ID: 27028243
[TBL] [Abstract][Full Text] [Related]
24. Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery.
Keung EZ; Hornick JL; Bertagnolli MM; Baldini EH; Raut CP
J Am Coll Surg; 2014 Feb; 218(2):206-17. PubMed ID: 24315890
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasis.
Ghadimi MP; Al-Zaid T; Madewell J; Peng T; Colombo C; Hoffman A; Creighton CJ; Zhang Y; Zhang A; Lazar AJ; Pollock RE; Lev D
Ann Surg Oncol; 2011 Dec; 18(13):3762-70. PubMed ID: 21614627
[TBL] [Abstract][Full Text] [Related]
26. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
[TBL] [Abstract][Full Text] [Related]
27. Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.
Suarez-Kelly LP; Baldi GG; Gronchi A
Expert Opin Pharmacother; 2019 Aug; 20(12):1503-1515. PubMed ID: 31136210
[No Abstract] [Full Text] [Related]
28. Liposarcoma: Multimodality Management and Future Targeted Therapies.
Crago AM; Dickson MA
Surg Oncol Clin N Am; 2016 Oct; 25(4):761-73. PubMed ID: 27591497
[TBL] [Abstract][Full Text] [Related]
29. Influence of age and subtype in outcome of operable liposarcoma.
Greto D; Saieva C; Loi M; Terziani F; Visani L; Garlatti P; Lo Russo M; Muntoni C; Becherini C; Topulli J; Campanacci D; Beltrami G; Scoccianti G; Muratori F; Bonomo P; Desideri I; Francolini G; Livi L
Radiol Med; 2019 Apr; 124(4):290-300. PubMed ID: 30421387
[TBL] [Abstract][Full Text] [Related]
30. Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma.
Traweek RS; Cope BM; Roland CL; Keung EZ; Nassif EF; Erstad DJ
Front Oncol; 2022; 12():1006959. PubMed ID: 36439412
[TBL] [Abstract][Full Text] [Related]
31. Primary anatomical site, adjuvant therapy, and other prognostic variables for dedifferentiated liposarcoma.
Gootee J; Aurit S; Curtin C; Silberstein P
J Cancer Res Clin Oncol; 2019 Jan; 145(1):181-192. PubMed ID: 30361927
[TBL] [Abstract][Full Text] [Related]
32. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.
Assi T; Kattan J; Rassy E; Nassereddine H; Farhat F; Honore C; Le Cesne A; Adam J; Mir O
Crit Rev Oncol Hematol; 2020 Sep; 153():103029. PubMed ID: 32593094
[TBL] [Abstract][Full Text] [Related]
33. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria.
Mariño-Enríquez A; Fletcher CD; Dal Cin P; Hornick JL
Am J Surg Pathol; 2010 Aug; 34(8):1122-31. PubMed ID: 20588177
[TBL] [Abstract][Full Text] [Related]
34. Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
Chamberlain FE; Wilding C; Jones RL; Huang P
Expert Opin Investig Drugs; 2019 Jun; 28(6):505-511. PubMed ID: 31010343
[No Abstract] [Full Text] [Related]
35. Current management options for liposarcoma and challenges for the future.
Kollár A; Benson C
Expert Rev Anticancer Ther; 2014 Mar; 14(3):297-306. PubMed ID: 24397249
[TBL] [Abstract][Full Text] [Related]
36. Getting up-to-date in the management of soft tissue sarcoma.
Blay JY
Future Oncol; 2018 May; 14(10s):3-13. PubMed ID: 29768050
[TBL] [Abstract][Full Text] [Related]
37. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
[TBL] [Abstract][Full Text] [Related]
38. Dedifferentiated Liposarcoma With Epithelioid/Epithelial Features.
Makise N; Yoshida A; Komiyama M; Nakatani F; Yonemori K; Kawai A; Fukayama M; Hiraoka N
Am J Surg Pathol; 2017 Nov; 41(11):1523-1531. PubMed ID: 28719466
[TBL] [Abstract][Full Text] [Related]
39. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.
Zhang YX; Sicinska E; Czaplinski JT; Remillard SP; Moss S; Wang Y; Brain C; Loo A; Snyder EL; Demetri GD; Kim S; Kung AL; Wagner AJ
Mol Cancer Ther; 2014 Sep; 13(9):2184-93. PubMed ID: 25028469
[TBL] [Abstract][Full Text] [Related]
40. Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma.
Alessandrini I; Percio S; Naghshineh E; Zuco V; Stacchiotti S; Gronchi A; Pasquali S; Zaffaroni N; Folini M
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
